Microbial compositions and methods of use for canine enteropathy and dysbiosis
The disclosure relates to isolated microorganisms—including novel strains of the microorganisms—microbial ensembles, and compositions comprising the same. Furthermore, the disclosure teaches methods of utilizing the described microorganisms, microbial compositions, and compositions comprising the same, in methods for treating or preventing gastrointestinal enteropathy or dysbiosis in canines. In particular aspects, the disclosure provides methods of treating or preventing morbidity and mortality caused by GI pathogenesis or autoimmunity.
1. A composition comprising:
(a) a purified population of bacteria comprising:
(i) a bacterium comprising a 16S nucleic acid sequence sharing at least 99.5% sequence identity to SEQ ID NO: 19;
(ii) a bacterium comprising a 16S nucleic acid sequence sharing at least 99.5% sequence identity to SEQ ID NO: 172; and
(iii) optionally, a bacterium comprising a 16S nucleic acid sequence sharing at least 99.5% sequence identity to SEQ ID NO: 326; and
(b) one or more carriers suitable for canine administration;
wherein the bacteria in the composition are lyophilized; and wherein the bacteria present in the composition are in an amount effective to improve one or more traits in a canine administered the composition.
2. The composition of claim 1 , wherein the purified population of bacteria comprises: a bacterium having a 16S nucleic acid sequence of SEQ ID NO: 19; and a a bacterium having a 16S nucleic acid sequence of SEQ ID NO: 172; and optionally, a bacterium having a 16S nucleic acid sequence of SEQ ID NO: 326.
3. The composition of claim 1 , wherein the purified population of bacteria comprises: a bacterium having a 16S nucleic acid sequence of SEQ ID NO: 19; a a bacterium having a 16S nucleic acid sequence of SEQ ID NO: 172; and a bacterium having a 16S nucleic acid sequence of SEQ ID NO: 326.
4. The composition of claim 1 , wherein the purified population of bacteria comprises: a bacterium deposited as NRRL B-67972; a bacterium deposited as NRRL B-67975; and a bacterium deposited as NRRL B-67977.
5. The composition of claim 1 , wherein the purified population further comprises one or more bacteria with a 16S nucleic acid sequence that shares at least 97% sequence identity with a nucleic acid sequence selected from: SEQ ID NOs: 237 and 327-331.
6. The composition of claim 1 , wherein the one or more carriers are selected from the group consisting of: an edible feed grade material, an aluminosilicate-containing mineral, a zeolite, calcium carbonate, a prebiotic, and a flavoring agent.
7. The composition of claim 6 , wherein the prebiotic is inulin, an oligosaccharide, and/or a vitamin.
8. The composition of claim 6 , wherein the flavoring agent is dried yeast, cheese flavoring, beef flavoring, fish flavoring, chicken flavoring, and/or pork flavoring.
9. The composition of claim 1 , wherein the one or more carriers are inulin and/or dried yeast.
10. The composition of claim 1 , wherein the bacteria are present in the composition at a concentration of at least 10 2 cells per gram of said composition.
11. The composition of claim 1 , wherein the composition is mixed with or sprinkled on top of animal food.
12. The composition of claim 1 , wherein the composition is formulated as a tablet, a pill, a capsule, a powder, a solution, a suspension, a food, or an emulsion.
13. The composition of claim 12 , wherein the composition is formulated as a dry food, a wet food, a kibble, or a raw food.
14. The composition of claim 1 , wherein the purified population of bacteria comprises: a bacterium deposited as NRRL B-67975; a bacterium deposited as NRRL B-67977, and optionally, a bacterium deposited as NRRL B-67972.
15. The composition of claim 1 , wherein the purified population of bacteria comprises: a bacterium comprising a 16S nucleic acid sequence sharing at least 99.5% sequence identity to SEQ ID NO: 19; a bacterium comprising a 16S nucleic acid sequence sharing at least 99.5% sequence identity to SEQ ID NO: 172; and a bacterium comprising a 16S nucleic acid sequence sharing at least 99.5% sequence identity to SEQ ID NO: 326.
16. The composition of claim 1 , wherein the one or more traits is an improvement in gastrointestinal health of the canine.
17. The composition of claim 1 , wherein the improvement in gastrointestinal health of the canine is reduced incidence of diarrhea, reduced dysbiosis, reduced enteropathy, reduced inflammation, improved fecal consistency, an increase in regular bowel movements, reduced incidence of constipation, or less straining during defecation.
18. The composition of claim 1 , wherein the one or more traits are selected from a group consisting of: reduced incidence of diarrhea, reduced dysbiosis, reduced enteropathy, reduced inflammation, decreased incidence of infectious or non-infectious disease, improved fecal consistency, increased regular bowel movements, improved fur or coat quality, increased appetite, increased energy, improved performance, and increased lifespan.